目的 探讨氨磷汀(amfostine,别名WR-2721)与香菇多糖(Lentian,LNT)、重组人粒细胞集落刺激因子(recombinant human granulocyte colony-stimulating factor, rhG-CSF)、重组人白介素-11(recombinant human Iinterleukin-11, rhIL-11)联合应用对辐射损伤小鼠的协同保护作用,为急性放射损伤的临床治疗提供一种新的治疗方案。方法 取70只ICR小鼠,分为7组,分别为对照组、模型组、5个用药组,除对照组外,其他组用60Co-γ射线1次照射,剂量率为0.8 Gy·min-1,累积剂量为5.0 Gy。测定小鼠照前第3天、照后第3、7及14 天的血常规,照后14 d处死小鼠,测定小鼠睾丸指数、骨髓DNA、骨髓有核细胞数、小鼠精子总数及睾酮和雌二醇含量。结果 WR-272与LNT、rhIL-11、rhG-CSF联合应用在白细胞、红细胞、血红蛋白指标中有促进恢复的作用(P<0.05或P<0.01),小鼠睾丸指数、骨髓DNA含量、骨髓有核细胞数及小鼠精子总数均有恢复作用。结论 WR-2721与LNT、rhIL-11、rhG-CSF联合应用具有较好的协同保护作用,是急性放射损伤治疗的一种较好的用药方案。
Abstract
OBJECTIVE To investigate the synergistic protection of amfostine(WR-2721) combined with Lentian(LNT), granulocyte colony-stimulating factor (rhG-CSF) and Iinterleukin-11 (rhIL-11) on radiation-injured mice, and provide a new therapeutic scheme for acute radiation injury. METHODS Seventy ICR mice were divided into seven groups, including control group, model group and five drug groups. Except the control group, the other groups were irradiated with 60Co-γ ray at a dose rate of 0.8 Gy·min-1 and a cumulative dose of 5.0 Gy. Routine blood tests were determined at 3 d before irradiation, 3, 7 and 14 d after irradiation, and the mice were sacrificed at 14 d after irradiation. Testicular index, bone marrow DNA, bone marrow nucleated cells, sperm count, testosterone and estradiol contents of mice were determined. RESULTS The drug treatment could promote the recovery of white blood cell (WBC), red blood cell (RBC) and hemoglobin(P<0.05 or P<0.01), and the testicular index, bone marrow DNA content, bone marrow nucleated cell number and sperm count of mice. CONCLUSION WR-2721 combined with LNT, rhG-CSF and rhIL-11 has a good synergistic protection, which is a good drug regimen for the treatment of acute radiation injury.
关键词
协同作用 /
电离辐射 /
氨磷汀 /
香菇多糖 /
细胞因子
{{custom_keyword}} /
Key words
synergistic effect /
ionizing radiation /
WR-2721 /
lentinan /
cytokines
{{custom_keyword}} /
中图分类号：
R963
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] JESSICA M M, TARA N F, THOMAS D H, et al. Enteral activation of WR-2721 mediates radioprotection and improved survival from lethal fractionated radiation[J]. Sci Rep, 2019, 9(1): 1949. Doi: 10.1038/s41598-018-37147-9.
[2] ÇAKIR Z Ü, DEMIREL C, KILCIKSIZ S C, et al. Melatonin can ameliorate radiation-induced oxidative stress and inflammation-related deterioration of bone quality in rat femur[J]. Inflammation, 2016,39(3):1134-1140.
[3] DING Y, CUI L, HUA M M, et al.Protective effect of angelica sinensis polysaccharide and astragalus polysaccharides on radiation injury in mice model of compatibility[J]. Mil Med J Southeast China(东南国防医药),2014,16(6):572-574.
[4] JI C F, YUE L. Review on chemistry and anti-tumor effect of Lentinan[J]. Chin Pharm J(中国药学杂志),2013,48(18):1536-1539.
[5] LIU X S, CAO X P, LOU C, et al. MTERFD1 promotes cell growth and irradiation resistance in colorectal cancer by upregulating interleukin-6 and interleukin-11[J]. Int J Biol Sci, 2019,15(12): 2750-2762.
[6] SONIS S T, PETERSON R L, EDWARDS L J,et al. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters[J]. Int J Med Sci,2000,36(4): 373-381.
[7] LAZARUS H M, ARMITAGE J O, GALE R P. Role of molecularly-cloned hematopoietic growth factors after acute high-dose radiation exposures[J]. J Radiol Prot, 2021,41(4):S478. Doi: 10.1088/1361-6498/ac0bff.
[8] SHAYNE M, HARVEY R D, LYMAN G H. Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity[J]. Expert Rev Anticancer Ther, 2021, 21(10):1145-1159.
[9] YANG E, CHOI H, PARK J S, et al. A first-in-human study of KMRC011, a potential treatment for acute radiation syndrome, to explore tolerability, pharmacokinetics, and pharmacodynamics[J]. Clin Transl Sci, 2021,14(6): 2161-2170.
[10] ZHOU F L, LIN T, LIU J, et al. The effect of Berberine combined with Ginsenoside Rg3 on Xenograth model of Nasopharyngeal carcinoma[J]. Chin Pharm J(中国药学杂志),2021,56(18):1496-1502.
[11] YANG D Q, NI W T, JIANG X W, et al. Progress in combination therapy to infection of carbapenem-resistant Pseudomonas aeruginosa[J]. Chin Pharm J(中国药学杂志),2017,52(14):1208-1211.
[12] GENG S H, XU M X, LIU X G, et al. Anticoagulation effect and bleeding risk of combination therapy with SATI and Asprin[J]. Chin Pharm J(中国药学杂志), 2018, 53(1):35-39.
[13] WANG X H, ZHANG W Z. Drug gability review on combination of ARB antihypertensive drugs and metolazone[J]. North West Pharm J(西北药学杂志),2016,31(1):70-75.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家科技重大专项重大新药创制项目资助(2008ZXJ09004-027)
{{custom_fund}}
PDF(912 KB)
